期刊文献+

HPLC梯度洗脱法测定复合物中特考韦瑞和烟酰胺的含量 被引量:3

Determination of content for tecovirimat and nicotinamide in the complex by HPLC with gradient elution method
原文传递
导出
摘要 目的建立HPLC梯度洗脱法同时测定特考韦瑞-烟酰胺复合物中特考韦瑞和烟酰胺的含量。方法采用Waters Symmetry C18色谱柱(4.6 mm×250 mm,5μm),以50 mmol/L磷酸二氢钾溶液-乙腈为流动相梯度洗脱,流速为1.0 ml/min,柱温为30℃,检测波长为224 nm,进样量为20μl。结果特考韦瑞和烟酰胺之间分离度良好;特考韦瑞在5~50μg/ml、烟酰胺在5~50μg/ml范围内峰面积与浓度线性关系良好;其平均回收率分别为100.76%和100.01%;该法的重复性及中间精密度均符合要求;检测用溶液在室温条件下放置24 h稳定。结论该法准确可靠,可用于复合物中特考韦瑞和烟酰胺含量的同时测定。 Objective To establish an HPLC method to determine the concentration of tecovirimat and nicotinamide in the tecovirimat/nicotinamide complex. Methods A Waters Symmetry C18 column( 4. 6 mm × 250 mm,5 μm) was used with 50 mmol/L KH2 PO4-acetonitrile as the mobile phase with gradient elution at a flow rate of 1. 0 ml/min. The column temperature was 30℃ and the detection wavelength was 224 nm. The injection volume was 20 μl. Results Tecovirimat and nicotinamide were separated completely. The calibration curves were linear within the range of 5 ~ 50 μg/ml for tecovirimat and 5 ~ 50 μg/ml for nicotinamide. The average recoveries were 100. 76% and 100. 01%,respectively. The repeatability and intermediate precision met the requirements. The test solution was stable within 24 h. Conclusion This method is reliable,so it can be used for the simultaneous determination of tecovirimat and nicotinamide in the complex.
作者 吕琳 洪伟 杨美燕 高春生 郭永学 钟武 L Lin;HONG Wei;YANG Mei-yan;GAO Chun-sheng;GUO Yong-xue;ZHONG Wu(School of Pharmaceutical Engineering,Shenyang Pharmaceutical University, Shenyang 1113000, China;Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing 100850, China)
出处 《军事医学》 CAS CSCD 北大核心 2018年第3期227-229,共3页 Military Medical Sciences
基金 国家科技重大专项资助项目(2017ZX09101-005-008-001)
关键词 特考韦瑞 烟酰胺 高效液相色谱法 梯度洗脱法 tecovirimat nicotinamide HPLC gradient elution method
  • 相关文献

参考文献2

二级参考文献23

  • 1刘硕谦,刘仲华,黄建安,田娜,陆英,罗国安.反相高效液相色谱法同时测定姜黄药材中3个组分的含量[J].分析化学,2005,33(3):309-312. 被引量:29
  • 2许舜军,李鸿燕,曾元儿,江滨.反相高效液相色谱法测定大黄药材五种蒽醌类成分的含量[J].时珍国医国药,2006,17(7):1201-1202. 被引量:17
  • 3Smith GL, McFadden G. Smallpox: anything to declare? [J]. Nat Rev Immunol, 2002, 2(7):521-527.
  • 4Tayavanagimatt SR, Stone MACL, Weimers W,等. 多晶型物形式ST-246和制备方法[P]. 中国专利: CN 103068232 A, 2013-04-24.
  • 5Bailey TR, Rippin SR, Opsitnick E, et al. N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: identification of novel orthopoxvirus egress inhibitors [J]. J Med Chem, 2007, 50(7):1442-1444.
  • 6Duraffour S, Snoeck R, de Vos R, et al. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures [J]. Antivir Ther, 2007, 12(8):1205-1216.
  • 7Smith SK, Olson VA, Karem KL, et al. ST-246 In vitro efficacy against smallpox and monkeypox [J]. Antimicrob Agents Chemther, 2008, 53(3):1007-1012.
  • 8Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge [J]. J Virol, 2005, 79(20):13139-13149.
  • 9Grosenbach DW, Berhanu A, King DS, et al. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice [J]. Proc Natl Acad Sci USA, 2010, 107(2):838-843.
  • 10Quenelle DC, Buller R, Parker S, et al. Efficacy of delayed treatment of ST-246 given orally against systemic orthopoxvirus infections in mice [J]. Antimicrob Agents Chemother, 2007, 51(2):689-695.

共引文献3

同被引文献10

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部